Deregistration notice
Open the filing on sec.gov
Lunai Bioworks Inc. (LNAI)
Nasdaq: LNAI · Pharmaceutical Preparations · Suite 906 Los Angeles, CA · filing with the SEC since 2011
The companyfiscal 2026, as filed
Revenue$51,992
Net income-$3.6M+98.0%
Earnings per share$-1.06+98.8%
Operating cash flow-$5.3M+32.8%
Cash$1.7M+1748.6%
Debtn/a
Shareholders’ equity-$9.0M+57.7%
Shares, diluted3,360,903+62.9%
Return on equityn/a
The recordfrom its filings
Filings in 202631
Newest filingNov 12 · 15-12G
Annual reportOct 13, 2026
Quarterly reportMay 15, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted2
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$3.6MCash from operations -$5.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Delisting notice
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Employee stock plan update
Open the filing on sec.gov
Registration amended after taking effect
Open the filing on sec.gov
Employee stock plan update
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Annual report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.